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Abstract 
In this project we researched and optimized an new synthetic route for R-Equol, 
a molecule that is attracting increasing interest for the medicine because of its 
phytoestrogenic properties and the chemoprevention of breast cancer. 
To reach this objective we start, from smaller building blocks, with the synthesis 
of Daidzein followed by a chemoselective borane reduction to obtain an olefin 
that will be hydrogenated enantioselectively with a commercial Ir-BARF catalyst. 
The increasing success of these catalysts even with this genre of substrates has 
already given good results with different catalysts in both e.e. and yield. 
For further researches we deuterate the Equol in the aliphatic O-ring and attempt 
a secondary synthetic route with an hydrogenation using QN-modified Pd. 
 
 
 
In questo progetto abbiamo studiato e ottimizzato una nuova via di sintesi per 
l’R-Equol, una molecola che sta suscitando sempre più interesse nella medicina 
per le sue proprietà ormonali e per la chemoprevenzione del cancro al seno. 
Per raggiungere il nostro obbiettivo siamo partiti da piccoli building blocks per 
sintetizzare la Daidzeina, processo seguito da una riduzione chemoselettiva con 
borano per ottenere una olefina che sarà idrogenata enantioselettivamente con 
Ir-BARF commerciale. 
Il crescente successo di questi catalizzatori anche con il nostro tipo di substrati 
ha già dato buoni risultati in resa ed e.e. 
Per ulteriori ricerche abbiamo deuterato l’Equol nell’O-ring alifatico, inoltre 
abbiamo tentato una seconda via di sintesi con una idrogenazione catalizzata da 
Pd modificato con chinina. 
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Abbreviations 
Bn  Benzyl 
CBS  Corey-Bakshi-Shibata 
DCM  Dichloromethane 
Dx                 Number of deuteriums in the molecule¨ 
e.e.  Enantiomeric excess 
ER   Estrogen receptor 
EtOD           D1-ethanol 
ip                  Isotopic purity 
IR                Infrared 
Me               Methyl 
MeOD         D1-methanol 
MOM  Methoxymethyl 
MS               Mass Spectra 
NaHMDS Sodium bis(trimethylsilyl)amide 
NMR           Nuclear Magnetic Resonance 
OY  Overall yield 
Ph  Phenyl 
PTC  Phase transfer catalysis 
r.t.  Room temperature 
THF             Tetrahydrofuran 
TMS  Tetramethyl silane 
TON  Turnover number (unit of substrate converted per time) 
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INTRODUCTION 
 
Chirality 
 
Chirality, a term coined by Lord Kelvin in the end of the 19th century, is a 
property held by the geometrical figures that are not symmetric so not 
superimposable in their mirror image. 
In everyday life we can find many objects that have this property, both natural 
and artificial. Our hands are the most immediate example we can see, but even 
the whole human beings are considered chiral. 
Geometrically this feature has no or little consequences, indeed a dice is chiral 
but this has no consequence in the probabilities, even the simple knot is chiral 
but not for this reason one will be easier to untie. 
In many sciences instead this property is more interesting because it is the 
source of many other features. In medicine we have dextrocardia that is the 
congenital defect that goes from having the heart situated in the right side of the 
body to having a completely mirrored body. In neuropsychology this 
phenomenon is visible in the control of language functions, which are related 
almost always only to the left hemisphere. However, the dominance of one 
hemisphere (which affects handiness) can affect the location of language 
specific brain areas. For this reason, left-handed people are generally excluded 
from language related brain studies. 
In physics we can see that just the chirality in both massive and massless 
particles: spins of electrons are the base of VSEPR theory, where the electrons 
occupy orbitals in pair. This happens because the electron can have two spins: 
½ and -½ that generate opposed magnetic moments so 2 electrons can stay in 
the same orbital because the magnetic moments balance the charge repulsion 
eliminating the total magnetic moment, a similar phenomenon is present even in 
light  and can be called helicity. 
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Fig. 1: Helicity in particles spin 
 
In biology we see that evolution has developed a lot of animals and plants that 
are chiral for example the flatfish that has evolved to swim on one side of the 
body, the male narwhal has developed the tusk, a protruding tooth on the left 
side of the upper jaw that looks like a horn and the fiddler crab had developed 
his claws differently, one for female courtship and one for eating. 
 
 
Fig. 2: Chirality in nature 
 
In chemistry the chirality has a fundamental role in the properties of molecules, 
while two enantiomers have exactly the same group and chemical-physical 
properties the structures are different and when they interact with other chiral 
molecules they show different behaviors. 
Most of the natural organic molecules present in nature and so even in our body 
are chiral, amino acids except glycine, for example, are chiral molecules and in 
nature we can find only one of the possible enantiomers. 
 
For this reason, every time our body interacts with a chiral molecule, the different 
enantiomers may have different effects in our body. It can be a different taste as 
R-Asparagine that is sweet while S-Asparagine is bitter, or different smell like R-
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Limonene that smells like lemon and S-Limonene that smells like orange. Many 
times different enantiomers have the same effects just with a different efficiency. 
Adrenaline, also called R-Epinephrine, is 10 times more efficient than its 
enantiomer and for this reason is used enantiopure. Sometimes is not needed to 
have a pure enantiopure molecule, like with Ibuprofen that is administered as a 
racemic mixture because the body automatically transforms the (R) enantiomer 
in the most active (S) enantiomer1. 
In other cases, enantiopurity is essential, this is the case of Penicillamine an 
antirheumatic in the (S)2 form that is toxic in the (R) form because it blocks 
vitamin B6. 
 
Asymmetric Synthesis 
 
So in most cases the purity of an enantiomer is a very important quality for the 
fine chemistry, for this reason the researchers in the universities and in the big 
pharmaceutical companies are constantly trying to find ways to obtain their 
product of interest as enantiopure as possible. There are three main approaches 
to obtain a single enantiomer: The resolution of a racemic mixture, the use of 
chiral reagents from the nature and the asymmetric induction. 
 
Racemic Resolution 
The chirality has been discovered by Pasteur in 1848 with the crystallization of 
ammonium tartrate he discovered that the crystals had a particular shape that 
was not superimposable on its mirror image and he found the presence of both 
the configuration of these crystals. This was the first resolution of a chiral 
compound, specifically it was a direct resolution because it happened through a 
simple crystallization. 
The common resolution used nowadays is different from the method utilized by 
Pasteur, it consist in the simple separation of the two enantiomers induced 
through the addition of an enantiopure resolving agent, this will produce two 
diastereoisomers that will behave as different substances and would therefore be 
separable. It is also possible to separate enantiomer by the use of chiral HPLC 
or by a reaction (kinetic resolution). With the kinetic resolution we exploit the 
10 
 
different kinetic constant of the same reaction for the two enantiomers, if at the 
same time we have even a racemization reaction that re-establish the equilibrium 
of the unreacted reagent we can have a theoretical yield of 100%. Except for this 
dynamic kinetic resolution method the HPLC and the classical resolution never 
go beyond 50% of yield, moreover is an expensive method that oblige us to do 
additional and repetitive steps to add and remove the resolving agent that at 
least can be recycled. However is the only way we know to obtain compounds 
whose synthetic route has not been developed yet. 
 
 
 
 
 
 
 
Fig. 3: Enantiomorphic sodium ammonium tartrate crystals observed by Pasteur (left), General 
resolution procedure with resolving agent (right). 
Chiral Pool 
The second strategy is the use of natural enantiopure molecules as building 
blocks for our final product, most of the times these molecules are sugars or 
amino-acids. This may be an advantage if our final product is similar to the initial 
substrate but may have big drawbacks if we want to obtain a more complex 
product. Not always we have chiral molecules close to the product and even if 
we have them we need molecules with the right chirality, in nature most of the 
times is present just one of the enantiomers for each optically active molecule. 
The lack of one of these two needs not always makes the synthesis impossible 
because we may invert the chirality at a certain point of the synthesis if we need 
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or we can add different building blocks to the initial substrate to obtain our 
product, but all these procedures add more unwanted steps in our synthesis that 
may make our route inconvenient and not efficient. 
Enantioselective Synthesis 
The enantioselective synthesis is the attempt to copy what before was nature’s 
monopoly of enantiopure molecules’ synthesis. Being the most recently 
discovered strategy and even the most convenient, this method induces the 
chirality through another chiral substrate, generally we divide further this field in 
chiral auxiliaries and chiral catalysts. 
A chiral auxiliary is an enantiopure molecule that, by being attached near to the 
prochiral center, will induce the formation of an enantiomer over the other. 
Introduced by Corey3 in 1978 this method became famous when Evans4 started 
to use oxazolidinones auxiliaries developing a library of available auxiliaries 
applicable in aldol reactions, alkylations, and Diels-Alder reactions. Although this 
technique is better than the resolution and most of the times better than using a 
chiral pool, we still add to our synthesis three additional steps: the covalent 
attachment of the chiral auxiliary to the substrate, one or more diastereoselective 
transformations and the detachment of the auxiliary from the compound 
obtained. 
 
 
Fig. 4: Example of an enantioselective alkylation with Evans’ auxiliary with different 
detachments
5
. 
 
In the asymmetric catalysis instead the chiral source is the enantiopure catalyst, 
when the substrate interacts with the catalyst the attack from the other reagent 
will be favored by one side over the other, creating a diastereoselectivity 
between the two forms of activated substrate. With this method is possible to 
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give the substrate optical purity without losing time and yield in additional steps 
by implementing the only chiral inductive step in the normal steps that are 
needed to obtain the product. 
William S. Knowles, Ryōji  Noyori and Barry Sharpless  where the first pioneer 
that introduced the asymmetric catalysis. Sharpless developed a set of 
enantioselective catalyzed oxidations6 while Knowles and Noyori7 developed 
enantioselective catalyzed hydrogenations with chiral catalysts. 
 
 
Fig. 5: Sharpless asymmetric epoxidation of allylic alcohols. 
 
 
Fig. 6: Noyori’s asymmetric hydrogenations (left), Noyori’s catalyst (right). 
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Among the asymmetric catalysts used there are even enzymes, these may be 
seen as the most specific catalyst found in chemistry but this may be either an 
advantage or a disadvantage. Because of this specificity due to the shape of the 
active site we can work only with particular substrates, moreover we have many 
limits in the reaction conditions, like pH, temperature, solvent and many other 
parameters that may cause the denaturation of the enzyme, however when we’ll 
have a working reaction we will generally have an excellent e.e.8 
The research is trying to expand the possible conditions of enzyme catalysts 
trying to make them more heat resistant and to explore the possibility to use 
solvents different from water9. 
Even if the research is making giant steps this asymmetric synthesis is still not 
so used in organic chemistry. 
 
Further developments: Organocatalysis 
From when the asymmetric catalysis has been discovered its use had spread in 
many laboratories all over the world. Initially the catalysts were transition metals 
complexes with chiral ligands or chiral-at-metal. 
This kind of catalyst can be used in low amount due to their high efficiency but 
they may need sometimes really drastic conditions and sometimes it may be 
needed to work with an inert atmosphere to avoid the oxidation of the metals, 
moreover most of these catalysts are extremely expensive. 
These conditions and the recent development of “green chemistry” have induced 
the development of a new field of catalysis by introducing the organocatalysis. 
These catalysts that consist in organic molecules have different advantages, 
generally they are not so toxic and resistant to oxidation so is not absolutely 
needed to work under inert atmospheres and with water-free solvents, moreover 
the price is not as high as the metal-complex even if the amount of catalyst 
needed is higher and the TON generally is lower. 
One of the first organocatalytic reaction has been discovered in 1974 by Parrish 
et al.10 using L-proline, a natural amino-acid, to catalyze an aldol condensation, 
but after this reaction there has not been a big development of this field until 
2000. In those years the articles about organocatalysis started to increase 
exponentially especially thanks to the contribution of Barbas, MacMillan and List 
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that developed further this field discovering new catalysts and mechanisms that 
represent the “ying and the yang” of asymmetric synthesis because depending 
by the mechanisms we can attach to our molecule a nucleophile or an 
electrophile as we can see in the following figures. 
 
 
Fig. 7: MacMillan Catalysts
11
. 
 
 
Fig. 8: Micheal addition with MacMillan Catalyst (imine mechanism). 
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Fig. 9: List & Barbas aldol condensation with L-proline (enamine mechanism)
12
. 
 
Another famous catalyst has been developed by Corey, Bakshi and Shibata13 
from L-proline, this is used in reductions with boranes, Diels-Alder and [3+2] 
cycloaddition. The discovery of this catalyst started with an analysis of the use of 
a chiral amino alcohol used as auxiliary for the hydroboration this initially led to 
the discovery of a mechanism that allowed the development of this catalyst. 
 
 
Fig. 10: CBS Catalyst activation and mechanism for hydroboration. 
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Another big family of organocatalyst are the alkaloids of Cinchona, this plant 
from South America contains 6 different versions of a singular structure. 
These alkaloids in addition to be really cheap have different interesting 
properties that have attracted the interest of researchers for their use as 
organocatalysts. 
 
Fig. 11: Alkaloids of cinchona present in nature. 
 
In nature there is not a complete couple of enantiomers of these 6 alkaloids but 
they have the interesting property to behave as 3 couples of pseudo-
enantiomers inducing the opposite chirality to their products. 
Moreover these catalyst are bifunctional because of the different groups present 
on them, the OH group can be a Lewis acid and H-donor while the amino group 
behaves as a base making these molecule usable as Brønsted basic catalysts. 
But the major interest lays in the many possibilities to derivatize these molecules 
so that they can be used for much more reactions, here we have some 
examples. 
 
Fig.12: Reduction with QN-AlH3
14
. 
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Fig. 13: Alkylation with derivatized QN as PTC
15
. 
 
Usually the common hydrogenations are catalyzed by Pd or Pt on charcoal or 
alumina, but cinchona alkaloids have shown interesting properties even with this 
reacton, on 1979 Orito et al.16 have used cinchonidine-modified Pt to 
hydrogenate methyl pyruvate obtaining an e.e. of 97%. 
Further studies have shown that the suitable substrates are those with an 
electron pair donor in α position of the carbonyl with better e.e. with keto-acids17, 
keto-esters18, keto-acetals19 and α-methyltrifluoride ketones20. 
Later has been discovered that Pd too has enantioselectivity with the 
hydrogenations of α,β-insaturated carbonyl to ketones or aldehydes but with a 
lower efficiency21. 
 
These modified catalysts are possible because of the interaction of the quinolinic 
part of the quinine with the metal layer while the quinuclidinic site orientates the 
substrate, a model has been proposed for the hydrogenation of ethyl 
piruvate22,23. 
 
 
Fig. 14: Model of interaction quinuclidine - Pt - Methyl pyruvate, B is the favourite position. 
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Asymmetric Hydrogenation with Ir catalysts 
 
Even with the last developments of organocatalysts, the asymmetric 
hydrogenations is still dominated by metals and the most common catalysts used 
to induce the chirality are Rh, Ru and Ir based complexes. 
Among these metals the Ir had a great development only in the last years, the 
reason for which it was not so used was due to the excessive stability of the H2 
adduct that fails to dissociate, the solution has been found by Crabtree24, 
developing some good Ir-based catalyst that are able to continue the catalytic 
cycle to the completion. In all the Crabtree catalyst the solvent is fundamental 
because all the protic solvents or those that could act as ligands were stabilizing 
the metal hydride. Obviously even the ligands have their importance, the high 
activity of the best Crabtree catalyst is due probably to its unique structure with a 
P-donor ligand and a N-donor ligand. Pfaltz25 decided to add chirality to this 
catalyst by using optically active phosphino-oxazoline ligands (PHOX), starting 
with this discovery the development of this new family of ligands. 
Between the new ligands there are the JM-PHOX developed by Burgess26 that 
give good and excellent e.e. with many olefins.  
Using a single bidentate ligand instead of two monodentate gives more 
conformantional rigidity to the complex that has been demonstrated to be an 
important factor for enantiomeric selectivity in asymmetric synthesis, these 
catalyst developed by Burgess have a too flexible ethyl ligand between the 
oxazine and the phosphino, on the base of this assumption Pfaltz27 develops 
again the ligands demonstrating that a Me on the oxazoline ring improves the 
enantioselectivity by increasing the rigidity of the structure. 
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Fig. 15: 1) Crabtree catalyst, 2) Ir-PHOX BARF, 3) Ir-JM-PHOX BARF, 4) Zhang Catalyst, 5) 
Pflatz Catalyst. 
 
The catalytic cycle for hydrogenation of alkenes with this family of catalysts has 
been studied through a Density Function Theory analysis (DFT), this method 
consists in a software modelling of the electronic structures of multiple-body 
systems like molecules or complexes. 
It was already known that the general mechanism was going through an 
oxidative addition of H2 and a reductive elimination, but just recent researches 
have proposed 3 different mechanisms and explored these with the Ir-PHOX 
catalyst (Fig. 15) and 2 similar substrates (Fig.18). 
All the mechanisms start with the reduction of the COD, in the first mechanism 
(Fig. 16, Mechanism A Ir+/Ir3+ cycle) analyzed by Chen28 we have subsequently 
the coordination of the Ir+ with the alkene and with the H2 molecule followed by 
the oxidative addition to form the hydride, then we have migratory insertion and 
reductive elimination with loss of the product and regeneration of the activated 
catalyst. 
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Fig. 16: Mechanism A. 
 
The mechanism B29 (Fig. 17, Ir3+/Ir5+ cycle) in addition to the coordination of the 
alkene and the H2 has the oxidative addition of another H2 in the first step and 
subsequent migratory insertion of one H from the coordinated H2 molecule to the 
alkene in parallel with the oxidative addition of the other to the Ir. Finally the 
reductive elimination and the product detachment complete the catalytic cycle. 
 
 
Fig. 17: Mechanism B 
 
The mechanism C (Fig. 18, Ir3+/Ir5+ cycle) is slightly similar to B but we have in 
the beginning a major stabilization due to the coordination of two solvent 
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molecules (DCM), moreover the second oxidative addition of H2 happens after 
the migratory insertion and not in parallel so the first H that attach the alkene is 
an hydride and is not coming directly from the coordinated H2 molecule but was 
one of the hydrides already attached to the Ir. 
The most thermodynamically favored mechanism for alkenes hydrogenation is 
the C, this has been explored further with the prochiral substrate whose 
hydrogenation has been already tested experimentally with the result of a high 
e.e. for the R-enantiomer. 
 
  
Fig. 18: Mechanism C with prochiral substrate S2 with the favourite structure (left), all the 
possible positions of the substrate in the complex (right). 
 
     
Fig. 19: Energy graph of the 3 possible mechanisms with S1 (left), substrates analyzed (right). 
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The substrate can interact in 4 different ways, 2 for each face and moreover the 
hydride formed with the first H2 oxidative addition can be oriented above or below 
the basal plane giving the possibility of 23 possible combinations. The analysis 
shows as the most favored the A (Fig. 19) with the hydride below the plane 
according to the laboratory experiments. 
 
We have to consider that this study has been done with only one particular 
catalyst and similar substrates, so even mechanisms A and C are not excluded 
with a catalyst with different ligands and/or substrates. 
 
Equol 
 
Equol is an isoflavandiol phytoestrogen (of the class of isoflavonoids). In nature 
we can find the (S) enantiomer as a metabolite of Formononetin, Daidzin and 
Daidzein, three isoflavones that can be found in soy30. 
 
 
Fig. 20: Isoflavonoids; 6) Daidzein, 7) Genistein, 8) Equol, 9) Formononetin 10) Biochanin A. 
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This molecule has been isolated for the first time from mare’s urine in 193231 but 
successively it has been found even in other animal species including cows, 
hens, monkeys, chimpanzees, dogs, mice, rats and pigs. In all the species the 
biosynthesis of Equol comes from a specific microorganism present in the gut. 
On 1942 a disease (called after this study “Clover disease”) in Australia that 
caused infertility, uterine abnormalities and endometriosis to sheep was caused 
by the presence of high amounts of Equol in the blood of the animals, this 
caused by the ingestion of high amounts of the indigen Trifolium subterranium 
clover in which Daidzein and Formononetin are abundant32. This study 
suggested (although didn’t prove) that Equol had phytoestrogenic effects. This 
hypothesis was confirmed only in the mid 60’ after the discovery of the first ER33 
whose binding affinity with (±)-Equol was much higher that the binding affinity 
with daidzein. 
From the day of its discovery there has been not so much interest in Equol with 
the discovery of its presence in human urine and that the presence of Equol in it 
is depending by the microflora of the body and by the diet this molecule started 
to attract the first interests. Later came out the so called Equol hypothesis, this 
hypothesis, proposed by Setchell et al.34 maintain that the people having the 
bacterial that convert Daidzein into Equol are more likely to derive benefits from 
isoflavone and soy exposure than those who don’t. This aroused even more 
interest in Equol as we can see from the graph. 
 
 
Fig. 21: Chronology of the publications on Equol. 
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Biological properties of enantiopure Equol 
The reason for its affinity with the ER is due to its strikingly similarity with the 
conformational structure of Estradiol.  
 
 
Fig. 22: Comparison of Equol with Estradiol. 
 
Most of the studies have been done with the chemically synthesized racemic 
compound or with the biosynthesized S-(-) Equol. The main difference between 
the two enantiomers has been shown only in the last years with comparisons35 of 
the binding affinity with ERα and ERβ. This comparison showed that (S)-Equol 
binds to ERβ more strongly than (R)-Equol, and this last one binds to ERα 
slightly more strongly than (S)-Equol. These results have increased the interest 
of the research for the (S)-Equol as a possible pharmaceutical or nutraceutical 
agent for a number of hormone-dependent disorders, however there was yet the 
possibility of its carcinogenicity to be checked, especially in the breast cancer 
because the ER are receptors that are over-expressed in around 70% of breast 
cancer36. Recent studies on different animal models have shown not only that 
(S)-Equol is not carcinogenic but that (R)-Equol is potently chemopreventive37.  
Other researches have shown that both the enantiomers have a myriad of other 
biological properties with the potential to be of value in many clinical areas: 
cardiovascular disease, osteoporosis, and menopausal symptoms, moreover an 
in-vitro study showed that Equol has the highest antioxidant activity between all 
the isoflavones. Several studies show Equol to be a vasorelaxant, inducing 
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endothelial and NO-dependent relaxation38, suggesting that equol may be helpful 
in reducing risk of cardiovascular disease. 
 
Synthetic strategies 
The studies done on Equol are not complete and most have not been made on 
human tissue so is still very long the path that researchers have to take for Equol 
to be a new drug and many are the obstacles that have to be passed. However, 
there is a growing interest in both the enantiomers of Equol. The research on 
these two compounds has always been hampered by the lack of an efficient 
method of synthesis has led many organic chemists in the research of an 
efficient synthesis of these components to obtain easily both of them in an 
enantiopure form. 
 
The first studies were based on synthesis of this compound in the racemic form, 
the most efficient consist in a simple hydrogenation of isoflavones such as 
Daidzein with 5-10% Pd/C as catalyst (20-30% w/w)39. 
 
 
Fig. 23: Catalytic hydrogenation of Daidzein. 
 
Even by having a high yield this method is starting from Daidzein and anyway we 
obtain only a racemic mixture that we should resolve if we want to study the 
enantiomeric properties. 
The very first attempt of enantioselective synthesis of a derivative of Equol has 
been done by Heemstra et al.40 with the help of a chiral auxiliary to obtain the 
enantioselectivity based on the work of Ferreira et al.41 that obtained only the 
dimethylated (S)-Equol. 
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Fig. 24: Heemstra Synthetic route with chiral auxiliaries. 
 
Even if with this first synthesis we obtained a product 99% pure and with an e.e. 
>99% the overall yield is just 9,8%. 
 
In another catalytic hydrogenation done by Steffan42 the CBS catalyst has been 
used to introduce the e.e. in the first step, the process followed by a protection 
whose sterical hindrance will orientate the successive reduction. In the end the 
product is obtained after a deprotection step with an OY of 44%. 
 
27 
 
 
Fig. 25: Steffan synthesis with CBS catalyst. 
 
The last catalytic hydrogenation attempted was done by Zhou et al.43 with an 
overall yield of 48,4% this reaction is even the one with the highest OY and an 
excellent e.e. (98%) 
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Fig. 26: Zhou’s synthesis with Ir catalyst. 
 
There have been even other synthetic strategies like the chiral pool, using a 
copper-mediated allylic transfer44 that start from (S)-lactic acid as a source of 
chirality. (OY: 31,6% non-considering the reagent synt.; e.e.: 91%). 
 
 
Fig. 27: Kobayashi’s synthesis using the chiral pool. 
 
And even cinchona alkaloids have been tested with this synthesis with an 
enantioselective PTC made from a derivative of cinchonine45 giving an OY of 
31,6%. 
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Fig. 28: Equol synthesis with a PTC. 
 
Finally, with an overall yield not reported but e.e. of 85% for Cat. A and 80% for 
the Cat. B. we have an addition catalyzed by a BINAP atropisomeric catalyst46. 
30 
 
 
 
 
Fig. 29: Equol synthesis (top) with derivatized BINAP (bottom). 
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PROJECT 
 
Even if the research is starting to explore this field of the synthesis with all the 
new methods developed for enantioselective synthesis the most common 
method to produce the enantiomers of equol is still the resolution of the 
racemate47. 
For this reason the aim of this thesis is to find a synthetic route for this 
compound in order to give to the medical research a fast and economic method 
to produce high amounts of both the enantiomers and to open the route of a 
possible industrial method of synthesis, in case Equol would become a drug. 
 
We want to use a catalyst of the family developed by Pfaltz, specifically with 
threonine derived phosphinite-oxazoline ligand and BARF counterion. This 
commercial catalyst will be used to hydrogenate a prochiral double bond situated 
on the hetero-ring. We choose to use this catalyst because we have seen 
excellent results in most of the hydrogenation of olefins with a small amount of 
catalyst. 
 
 
Fig. 30: Ir-BARF catalyst (A). 
 
To achieve our hydrogenation we need to have a substrate with a simple 
insaturation and without alcoholic groups that could coordinate irreversibly with 
the catalyst and/or destroy the other ligands. 
In order to obtain the dehydroequol we decided to reduce the keto group present 
on Daidzein, the particular combination of groups on the hetero-ring of Daidzein 
gives us the possibility to use a specific borane reducing agent to obtain 
straightly our intermediate of interest. 
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Fig. 31: Project retrosynthesis. 
 
Boranes are between the weakest reducing agent used in organic chemistry, 
these chemicals have been used for hydroboration and for the partial reduction 
of carbonyls, having a chemoselectivity for electron rich carbonyl-groups borane 
are favored the reduction of carboxylic acid over esters and ketones. 
Even with amides we have the complete reduction of the carbonyl group, this is 
due to the higher electron density. 
 
Fig. 32: General reduction with borane of carbonyl with an electron donor in α. 
 
Daidzein has an α,β-unsaturation and an oxygen atom on the hetero-ring we 
want to reduce, we think that this system can induce an electron pushing that 
may emulate the mechanism that we have for the amides. 
However, there is the presence of the double bond that can be hydroborated 
while we want to keep it trying to reduce only the carbonyl. For this reason we 
decided to use 9-BBN. This borane, invented by Knights and studied by him and 
Brown48 has proven more reactive and able to be much more regioselective for 
the less hindered sites. 
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While many of the synthetic route used in other articles started from Daidzein, 
we want to develop a complete synthetic route by starting from smaller building 
blocks to synthesize this product using a procedure developed by our laboratory 
for general isoflavones. 
 
Fig. 33: Retrosynthesis of Daidzein. 
 
During our work we will even produce racemic Equol through a simple Pd-
catalyzed hydrogenation of Daidzein that has been proved efficient already and a 
D-labelling through a D2 Pd-catalyzed deuteration in order to produce a molecule 
for further studies in our lab (complete deuteration). 
After the completion of this part of the project we tried to develop a shorter and 
cheaper route to obtain e.e. using Quinine as organocatalyst supported by 
Pd/Al2O3 for the hydrogenation step. This choice has come because of the high 
price of the Ir-Catalyst and the number of additional steps that are required in 
order to use such catalyst. Seeing the feasibility of the Daidzein catalytic 
hydrogenation we wanted to avoid to split the complete reduction of the groups 
on the heteroring in 2 steps and even to avoid the protection & deprotection but 
still trying to obtain a good e.e. 
 
Fig. 34: Second synthetic route analyzed. 
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RESULTS AND DISCUSSION 
 
Step 1: Synthesis of Deoxybenzoin 
 
For the synthesis of Daidzein (4) we used the method developed by Hase49 
through 2 steps one-pot. We start by bonding Resorcinol (1) and 4-
Hydroxyphenylacetic acid (2) with a Friedel-Crafts alkylation using as solvent the 
BF3Et2O obtaining a deoxybenzoin (3) (table 1). This reaction is followed by the 
closure of the central O-ring through a concerted reaction consisting in activated 
DMF as carbon source acting as an electrophile that will be attached by the 
deoxybenzoin: first by the aliphatic carbon then by the alcoholic oxygen on the 
ring (table 2). 
These steps have been the most problematic in our synthetic route, I found the 
experimental data of Hase impossible to reproduce, a problem that has been 
confirmed by other researchers50. 
 
 
Fig. 35: Steps 1 & 2 one pot. 
 
The problems in these steps lay not only in the reaction but also in the workup 
process. After trying and failing to reproduce the experiment with the original 
procedure, we initially increased the reaction times of the first step (Table 2: 
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entry 3-6) since we were expecting an almost complete reaction and the TLC 
were still showing reagents present in the reaction mixture (Table 2: entry 1, 2). 
After entry 6 in table 2 we decided to focus on the first step, deciding to increase 
the T as suggested by Nair51 obtaining a slightly better yield in a shorter amount 
of time optimizing the first step. 
 
Table 1: Screening of the T for the step 1. 
 
 
 Entrya  Time T Yield 
1 2 h 70°C 74,9%b 
2 20’ 120°C 59,8%b 
3 16’ 120°C 63,2%b 
4 7’ 120°C 79,5%c 
5 22’ 115°C 78,8%d 
6 17’ 115°C 80,1%c 
a: BF3Et2O : 1 : 2 = 20:1:1 (mol.) 
b: red-orange colour (impurities) 
c: yellow colour 
d: orange colour (impurities) 
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Step 2: O-ring closure 
 
Table 2: Optimization of the synthesis of Daidzein in 2 steps. 
 
                              STEP 1                          STEP 2 
Entry Time T Time T O.Y. 
1 1h 70°C 1h 30’ 80°C 13,0% 
2 1h 70°C 1h 30’ 70°C 14,2% 
3 24h 70°C 4h 10’ 70°C 28,0% 
4 24h 70°C 18h 14’ 70°C 38,5% 
5 39h 30’ 70°C 28h 70°C 41,3% 
6 43h 70°C 20h 70°C 18,5% 
7 30’ 100°C 2h 70°C 24,2% 
8 20’ 120°C 19h 70°C 38,6% 
9 15’ 115°C 51h 70°C 73,6% 
10 15’ 115°C 51h 80°C 68,9% 
a: DMF : BF3Et2O = 5:4 (mol) 
 
The second step has been more complex to analyze, initially we decided not to 
increase the reaction time too much in order to avoid what seemed like a general 
decomposition of the reagents or the product that turned the reaction mixture first 
red then dark and viscous like tar. However, even in the second step the 
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intermediate never reacted completely, so we decided to try to keep the reaction 
until the complete depletion of it. To our great surprise this optimized the reaction 
up to a yield of 73.6% after a prolongation of the second step from the initial 1h 
30’ to 50h (Table 2: entry 9). 
Even with the incomplete reactions the separation gave us big problems, 4 is 
really insoluble in most of the common solvents except ethanol52, methanol 
(around 0,1 mg/mL) and DMF and DMSO (10 mg/mL and 30 mg/mL). 
Initially we attempted recrystallization with ethanol and after with methanol as 
written in the article but this separation is inefficient both for the amount of the 
product recrystallized and the purity. 
We tried a solvent screening in test tube to find good candidates as 
recrystallization solvent or solvent mixture. 
 
Table 3: Solvent screening for recrystallization. 
Solvent Soluble (r.t.) Soluble (b.p.) Recrystallization 
Toluene NO NO NO 
EtOAc:MeOH 
(2:1) 
NO YES NO 
EtOAc:MeOH 
(3:1) 
NO incomplete NO 
EtOAc:MeOH 
(4:1) 
NO NO NO 
EtOAc:MeOH 
(5:1) 
NO NO NO 
Acetone NO YES NO 
Acetone:MeOH 
(1:1) 
partial YES NO 
1-Propanol NO YES traces 
2-Propanol NO YES traces 
1-Butanol NO YES traces 
2-Butanol NO YES traces 
DMF YES YES NO 
EtOAc NO NO NO 
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THF NO YES NO 
Benzene NO NO NO 
THF:Acetone 
(1:1) 
incomplete YES traces 
THF:Acetone 
(1:2) 
incomplete YES traces 
THF:Acetone 
(2:3) 
incomplete YES NO 
H2O NO incomplete traces 
MeOH:Toluene NO YES NO 
1-Propan1ol : 
ciclohexene 
NO YES YES 
Propan1ol : 
ciclohexene 
NO YES YES 
a: Test with approx 10mg of 4 in 3mL of solvent, results after 1 week. 
 
The few good candidates proved themselves inefficient too, we decided so to 
pass to another purification method, for a short time we considered a 
chromatographic column and we did also a screening for the solvent mixtures 
but its low solubility in solvents and the extreme complexity of the only suitable 
solvent mixture make us drop this separation method. Finally, we decided to 
simply clean the product from its impurities with cold methanol, the choice of this 
solvent was due by the fact that even the solubility properties of the impurities 
are similar to 4. 
 
After optimizing the synthesis of 4 and obtaining good amount of it we planned 
the following steps of our synthesis. Our plan was to obtain only a prochiral 
unsaturation on the O-ring that would allow us to use our Ir-BARF catalyst to do 
an asymmetric hydrogenation. 
To use the Ir-BARF catalyst we need to protect the alcoholic groups because 
they would destroy it. 
We decided to use BnCl for the protection and 9-BBN to eliminate the keto 
group. Initially we planned to try both the possible paths to obtain the protected 
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Dehydroequol (6): using as first reaction the protection and using as first reaction 
the reduction. 
 
Step 3: Protection 
 
Our first attempt was using the protection first, thinking we would have less 
troubles with the 9-BBN used in the reduction. This first attempt was successful 
and gave an excellent yield. Moreover, the isolation of the DiBnDaidzein (5) is 
really simple with recrystallization. 
The simplicity of the separation and purification suggested us to try it with using 
directly the crude 4 from the previous steps with a bigger excess of BnCl. The 
first attempt gave a really low yield (Table 4: entry 2) and the HPLC revealed the 
presence of many products, while second attempt with a higher excess of BnCl 
has given again an excellent yield (Table 4: entry 3). 
 
Table 4: Protection step with BnCl 
 
 
Entry Time BnCl : 4 (mol) Reagent 4 Yield 
1 3h 2,08 Pure (>99%) 91,5% 
2 1h 33’ 2,22 Crude (73,6%) 10,3%a 
3 1h 42’ 2,97 Crude (73,6%) 95,6% 
a: crude product yield. 
 
This has solved the problem we had with the separation of 4 from its impurities, 
seen this results we decide to attempt, without so much hope, a three-step one-
pot reaction trying to obtain 5 from the initial reagents in one pot. We obtained no 
results from this so we have not tried this strategy anymore being already 
satisfied with the results obtained so far. 
At this point we decided to not try the inverse order of reactions because we 
would lose the separation advantage given by the dibenzylation. 
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Step 4: Reduction with 9-BBN 
 
We proceeded so with the reduction reaction, trying initially with a big excess of 
reducing agent and obtaining a good yield (Table 5: entry 1), we tried then to see 
the results by using a lower excess of 9-BBN obtaining poor results (Table 5: 
entry 2). The biggest amount of yield was around 60% when we increased more 
the 9-BBN (Table 5: entry 3) revealing that a big excess is positive for the yield 
but not convenient. Leaving the reaction for more time seems to eliminate most 
of the product and to produce impurities (Table 5: entry 6-7). 
We didn’t try to use different solvents because protic solvent would have 
interfered in the reaction by doing unwanted acylation or by destroying the 9-
BBN. 
 
Table 5: Step 4, Reduction with 9-BBN. 
 
 
Entry Time 9-BBN (eq) Yield 
1 22h 18’ 8,5 59,8% 
2 22h 16’ 5,0 4,5% 
3 22h 00’ 10,1 59,9% 
4 14h 57’ 8,7 52,7% 
5 15h 58’ 8,7 57,9% 
6 62h 23’ 10,5 0%a 
7 41h 37’ 9,1 0%a 
a: too many impurities, traces of product inseparable 
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Fig. 36: 9-BBN reduction mechanisms and possible products. 
 
For this reaction we had hypothesized two mechanisms and two possible 
products, initially we have in both the reduction of the carbonyl with attach of it to 
the borane, the mesomeric effect of this special substrate and the sterical 
hindrance favors the initial attack and permit the elimination of 9-OBBN obtaining 
an intermediate stabilized probably by the temporary aromaticity. Subsequently 
we need have a second reduction, in this case we have two possible targets the 
C=C (blue path) or the C=O+ (red path). The steric hindrance seems to play a 
role even here, moreover the C=O+ is more polar so the red mechanism seems 
favored over the blue. The NMR, confronted to the NMR databases, confirm our 
hypothesis showing 6a as the major product and just traces of 6b. 
 
Step 5: Reduction with Ir-BARF 
 
Once we have eliminated the keto group and we have left on the O-ring only the 
unsaturation we started to try the hydrogenation with our Ir-BARF. We used as 
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model the procedure of Pfaltz27 and as catalyst we used the commercial one 
showed in project chapter (A). 
The reaction time in the article of Pfaltz for the hydrogenation of aryl-olefins is 
just 2 h with 50 bar of H2 and the solvent used is DCM, even in this experiment 
we didn’t checked the effect of different solvents because most of the others 
would permanently deactivate or destroy the catalyst23. 
The initial result had a really poor yield and increasing the time didn’t improve the 
reaction in a significant way (Table 6: entries 1-4). This has been solved by 
drying completely the solvent; initially the solvent contained around 3 ppm of 
water. Since the catalyst with the BARF- counter-ion was resistant to small traces 
of water53 and rigorous exclusion of water was not necessary we decided to not 
dry it completely. After the first attempts, showing almost no reactivity we 
decided to dry the solvent through distillation under CaH2 and storage under 
molecular sieves 3Å54. This allowed the reaction to happen with an excellent 
yield of (R)-DiBnEquol (7) showing that even small traces of water are enough to 
deactivate completely all this catalyst. 
 
Table 6: Step 5, asymmetric hydrogenation 
 
 
Entry Time Yield 
1 10 h 0% 
2 66 h 5,5% 
3 90 h 11,5% 
4 149 h 12,0% 
5 10 h 62,4% 
6 22 h 97,0% 
 
After optimizing the reaction we produced racemic Equol (±8) with a simple 
hydrogenation of 4 to test the chiral column and the eluent. Then we deprotected 
the -OH of 7 through a hydrogenation with Pd/BaSO4 and analyzed the e.e. 
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through an HPLC with inverse phase, comparing it with ±8 synthesized with a 
Pd/C catalyzed hydrogenation. 
 
Hydrogenation of Daidzein to (±)-Equol with Pd/C 
 
Table 7: Hydrogenation of Daidzein. 
 
 
Entry Time Cat. (% m/m) Yield 
1 27h 10’ 200% 74,3% 
2 18h 21’ 20% 87,1% 
3 24h 20%a 0% 
a: using Pd/BaSO4 
 
Initially we were using a procedure that was using a huge amount of catalyst55 
the high amount of catalyst was justified in the article by the low reactivity of 4, 
however for us even with 1/10 of the amount suggested the reaction seems to 
work perfectly and less product is kept by the charcoal. 
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Step 6: Hydrogenation to Equol with Pd/C 
 
Table 8: Deprotection of 7 
 
 
Entry Time Cat. (% m/m) Yield 
1 3 h 10% 95,1% 
 
The deprotection of 7 has been made with Pd/BaSO4, a poisoned catalyst, to 
avoid every minimal unwanted hydrogenation. 
The HPLC revealed that we obtained an e.e. of 97%. 
 
Fig. 37: HPLC graph of racemic Equol. 
 
Fig. 38: HPLC of our final product. 
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Deuteration to D4-Equol with Pd/C 
 
After having improved the hydrogenation of 4 we used the same procedure to 
obtain labelled Equol using D2. This product will be used by a colleague for 
further deuterations of the aromatic rings.  
 
Table 9: Deuteration of Equol. 
 
 
 Entry  Time Solv. 
(saturation) 
Cat:4 
(% m/m) 
Yield Isotopic 
purity 
1 24h 36’ EtOH 20% 68,61% 0% 
2 48h 49’ EtOD 10% 90,70% >99% 
 
Completed this part of the project we attempted and hydrogenation of 4 with 
Pd/Al2O3 and quinine as modifier. 
Hydrogenation with QN-modified Pd 
 
It is known that the modifier poisons the catalyst itself so we use as reagent the 
DiBn-Daidzein to check if the catalyst is able to deprotect the alcohol or if it is 
totally deactivated.  
We used a small amount of reagent in a big amount of catalyst, in entry 1 we 
decided to add more catalyst because after 24h there were no trace of activity, 
the rate QN : Pd was already lower compared to the amounts used in other 
studies21,c, but even decreasing the amount of QN (entry 2) the reaction never 
goes to completion being able only to deprotect the OH but not to hydrogenate 
the carbonyl and the double bond. This may be due to the big sterical hindrance 
that impede 4 to attack to a catalyst modified with QN. 
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Table 10: Hydrogenation with QN-modified Pd 
 
 
Entry Time Cat : 5 (m/m) QN : Pd 
(m:m) 
Yield 
1 51h 8:5a 5:6b 0% 
2 66h 3:1 2:3 0% 
a: initial rate = 6:5 after 24h more catalyst has been added to reach the rate in the table 
b: initial rate = 3:2 after 24h more catalyst has been added to reach the rate in the table  
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CONCLUSION AND FUTURE DEVELOPMENTS 
 
In this thesis we have achieved the objective to experiment and develop a new 
path for the synthesis of Equol with an overall yield of 38% and a e.e. of 97%. 
Deciding to not start from Daidzein but to synthesize it in the beginning of our 
path has decreased the expenses but has revealed to be one of the weakest 
point of our path, the decision to not analyze singularly the second step was due 
to the will to improve it in the one-pot procedure estimating its yield through the 
yield of the first step. 
The decision to reduce the keto group with the 9-BBN has revealed an 
interesting mechanism of the hydroboration further studies could be done in this 
argument through the deuteration of 9-BBN with D2 according to Nelson
56 to 
have a further confirmation and a new labelling of equol. 
The necessity of a high excess of this reagent for this reaction is probably linked 
to the last step of the mechanism where we have the attachment of 9-BBN to the 
C=O+, we suppose this because from the TLC seems that the first attachment 
happens in the first 2 hours of the reaction showing a new fluorescent spot that 
never disappears, we attempted to isolate what we were thinking was the 
intermediate but without success. 
For the key step of our path, the hydrogenation through Ir catalyst, we used a 
commercial catalyst that had previously showed really good results in the 
hydrogenations of aryl substituted olefins and even with our intermediate we 
obtained an excellent result. This could be further improved by testing different Ir 
catalyst considering the possible mechanisms that have been proposed for this 
catalyst. 
The necessity for a protection and deprotection increased the length of our 
synthesis, for this reason we decided to try the hydrogenation with QN-modified 
Pd on alumina, previous hydrogenations with Pd/C have reduced completely 
both the carbonyl and the unsaturation making us hope to obtain the same result 
with an e.e., even obtaining not a complete reduction but only a reduction of the 
unsaturation would anyway have shortened the synthetic route. 
We used only QN as modifier because due to the extreme similarity of all the 
alkaloids of cinchona we wanted just to explore the potential of this route, 
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obtaining just Daidzein and just minimal traces of other products suggested us to 
stop developing this route. 
The substrates previously used for this asymmetric hydrogenation were smaller 
and able to coordinate with both the alcoholic group and the aminic nitrogen on 
the QN, our molecule, being flat and having the OH groups in the extremities has 
not only problems in the occupation of the active site under the quinuclidine but 
in case it would, probably the difference of energy between re and si face would 
be almost none. 
The possibility to obtain better result in the synthesis of Equol with this strategy 
could be tested using a smaller substrate. 
We have seen that good result have been obtained in the synthesis of O-DMA 
through the same process of friedel-craft acylation used by us in the very first 
step47. 
So it may be a good idea to explore the asymmetric hydrogenation of 2-(4-
hydroxyphenyl)-propionic acid and, in case of success, try to develop a new 
synthesis starting from here. 
 
 
Fig. 39: possible new route. 
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EXPERIMENTAL SECTION 
 
Reagents 
 
From Sigma-Aldrich: 
Resorcinol (ReagentPlus) 
BF3·Et2O (≧47% BF3) 
9-BBN (0,5M in THF) 
Pd/C (10% m/m) 
Pd/BaSO4 (10% m/m) 
Pd/Al2O3 (5% m/m) 
d1 EtOD (>99,9%) 
DCM 
DMF 
 
From KeboLab: 
4-hydroxyphenyl acetic acid 
From Merck: 
MeSO2Cl 
BnCl 
 
From Fisher Chemicals: 
K2CO3 (dry) 
 
From Altia Oyj.: 
EtOH (96%) 
 
The water content of every solvent for the step 1-2 one pot, 3 and 5 has been 
checked with a Karl-Fischer titration. 
 
Instruments 
 
All the products have been analyzed with H1-NMR and C13-NMR spectroscopy 
with a Varian Mercury 300 MHz at room temperature. The reference is TMS in all 
the samples in CDCl3 and the solvent in all the samples in DMSO. 
To indicate the multiplicity we used the following abbreviations: s, singlet; d, 
doublet; t, triplet; q, quartet; m, multiplet; bs, broad signal. 
The reactions have been followed through TLC and the purifications for the 
analysis have been made through column (except for the Step 1-2 one pot and 
Step 3 in which recrystallization is used) with silica. 
The solvents have been used without further purification if not stated otherwise, 
the amount of water in solvent has been determined though a Karl-Fisher 
titration in a Mettler Toledo DL32 coulumeter titrator. 
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For additional analysis to confirm our product and to check the isotopic purity of 
the deuterated ones a MS has been taken of all of them in a EI-MS Jeol JMS-
700. 
The enantiomeric excess has been analyzed with a Polarimeter Jasco DIP-1000 
and determined with a column Cyclobond I RSP 2000; 250 x 10mm; Bonded 
phase: (R,S)-Hydroxypropyl modified beta-cyclodextrin. Eluent used ACN : aq. 
HCOOH 1% 35:65, 3,5 mL/min. 
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Optimized procedures 
 
STEP 1 (Table 1) 
Synthesis of 1-(2,4-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethanone  (3) 
A mixture of 1 (1,1011 g, 1 mol) and 2 (1,5216 g, 1 mol) are inserted in a dry, 2-
neck round bottom flask and dried overnight under vacuum, the flask has been 
refilled with Ar from a balloon attached to the flask and evacuated 3 times 
leaving Ar in the end. BF3∙Et2O (25mL, 20 mol eq) is added dropwise and the 
reaction mixture is left under magnetic stirring for 15’ at 115°C. The reaction was 
monitored with TLC in DCM:EtOAc (7:2). 
The product is extracted with DCM and purified (if needed) with a column using 
DCM:EtOAc (7:5) as eluent. 
Yield: 80,1% 
 
1H-NMR: 3,37 (dd, 1H J1= 2,4 Hz J2= 9,0 Hz), 4,12 (s, 2H), 6,24 (d, 1H J= 2,4 
Hz), 6,75-6,60 (m, 2H), 7,12-7,00 (m, 2H), 7,92 (d, 1H, J= 8,7 Hz), 9,26 (s, 1H), 
10,63 (s, 1H), 12,59 (s, 1H) 
13C-NMR: 43,26; 102,45; 108,20; 112,05; 115,20; 125,16; 130,33; 133,56; 
164,70; 164,87; 202,67. 
MS-EI: 244 (24%), 137 (100%), 122(10%), 107(18%), 97(11%), 81(16%), 
69(17%), 58(82%) 
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STEP 2 (Table 2) 
Synthesis of Daidzein  (4) 
 
A mixture of 1 (1,1011 g, 1 mol) and 2 (1,5216 g, 1 mol) are inserted in a dry, 2-
neck round bottom flask and dried overnight under vacuum, the flask has been 
refilled with Ar from a balloon attached to the flask and evacuated 3 times 
leaving Ar in the end. BF3∙Et2O is added dropwise and the reaction mixture is left 
under magnetic stirring for 15’ at 115°C. The reaction was monitored with TLC in 
DCM:EtOAc (7:2). 
When the reaction is completed the reaction is cooled down to 0°C and dry DMF 
(15 mL) is added dropwise successively MeSO2Cl (2,4 mL) is mixed with DMF (4 
mL), cooled to 0°C and added dropwise to the reaction mixture. 
The temperature is increased to 80°C for the first 24h then decreased to 70°C for 
the final 24h. The reaction is monitored with TLC in DCM:EtOAc (7:2). 
The reaction is quenched in a sol. of NaOAc, the reaction flask is cleaned with 
the minimum amount of methanol. 
The quenched reaction is kept under vacuum to eliminate most of the methanol 
and is left to rest for 1 week. 
Successively the reaction mixture is filtered and 4 is cleaned until the desired 
purity with methanol or ethanol (the time intervals between adding the solvent 
and filtering has to be at least of 1 day). 
Yield: 73,6% 
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1H-NMR: 6,69-6,88 (m, 3H), 6,94 (d, 1H, J=2,4 Hz), 7,38 (m, 2H, J=8 Hz), 7,96 
(d, 1H, J=8,7 Hz) 8,27 (s, 1H), 9,51 (s, 1H), 10,75 (s, 1H). 
13C-NMR: 102,08; 114,93; 115,10; 116,63; 122,53; 123,48; 127,27; 130,05; 
152,77; 157,15; 157,40; 162,47; 174,46. 
MS-EI: 254(78%), 137(39%), 118(21%) 
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STEP 3 (Table 3) 
Synthesis of 7-(benzyloxi)-3-(4’-(benzyloxi)phenyl)4H-chromen-4-one  (5) 
 
The compound 4 (1g, 4,2 mol) and K2CO3 (1,42 g, 2,4 eq) are inserted in a dry, 
2-neck round bottom flask and dried overnight under vacuum, the flask has been 
refilled with Ar from a balloon attached to the flask and evacuated 3 times 
leaving Ar in the end. Successively DMF (20 mL) is added through a septum and 
the reaction mixture is stirred magnetically until complete dissolution. 
BnCl (1mL, 2,05 eq with pure 4, 1,5 mL, 3 eq with crude 4) is added dropwise 
and the reaction mixture is left stirring for 2h at 95°C monitoring the reaction with 
TLC in DCM:EtOAc (7:2). 
The reaction is quenched in distilled water, cooled in ice and filtered. If some 
daidzein is present or if the daidzein used is the crude product of the previous 
steps further purification in a flash column with DCM is needed. If the Daidzein 
used was not purified the purification is done through recrystallization in DCM. 
Yield: 95,6% 
 
1H-NMR: 5,03 (s, 2H), 5,10 (s, 2H), 6,85 (d, 1H, J=2,4 Hz), 6,90-7,15 (m, 3H), 
7,23-7,46 (m, 12H), 7,83 (s, 1H), 8,15 (d, 1H, J= 8,7 Hz) 
13C-NMR: 70,20; 70,69; 101,39; 115,05; 115,15; 118,77; 123,63; 125,01; 127,58; 
127,65; 128,02; 128,10; 128,55; 128,74; 128,91; 130,29; 135,88; 137,09. 
MS-EI: 434(55%), 343(29%), 91(100%), 77(18%) 
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STEP 4 (Table 4) 
Synthesis of 7-(benzyloxi)-3-(4’-(benzyloxi)phenyl)2H-chromene  (6a) 
 
The compound 5 (0,5 g 1,17 mol) is inserted in a dry, 2-neck round bottom flask 
and dried overnight under vacuum, the flask has been refilled with Ar from a 
balloon attached to the flask and evacuated 3 times leaving Ar in the end. 
Successively THF (approx 78 mL) is added while stirring until all the compound 
is dissolved and 9-BBN (8,5 eq) is added dropwise. The reaction mixture is left 
under stirring for 22 h and is monitored with TLC in DCM. When the reaction is 
complete it is quenched in water and filtered. If further purification is needed is 
possible to purify in a flash column with DCM. 
Yield: 59,9% 
 
1H-NMR: 5,05 (s, 2H), 5,06-5,12 (m, 2H), 5,09 (s, 2H), 6,50-6,57 (m, 3H), 6,68 
(s, 1H), 6,69-7,05 (m, 2H), 7,26-7,49 (m, 12H) 
13C-NMR: 31,08; 67,44; 70,26; 102,55; 108,38; 115,13; 115,24; 116,81; 118,32; 
125,64; 125,93; 127,55; 127,61; 128,12; 128,62; 128,73; 128,76; 129,94; 137,00. 
MS-EI: 420(55%), 329(64%), 106(55%), 105(54%), 91(100%), 77(48%) 
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STEP 5 (Table 5) 
Synthesis of (R)-7-(benzyloxi)-3-(4’-(benzyloxi)phenyl)chroman  (7) 
 
The compound 6a (0,080 g, 1,91*10-4 mol)  is inserted in a dry test tube for 
autoclave and dried overnight under vacuum, the flask has been refilled with Ar 
from a balloon attached to the flask and evacuated 3 times leaving Ar in the end. 
keeping everything under Ar atm the catalyst A (9 mg, 0,03 eq) then dry DCM (9 
mL) are added and the test tube inserted in the autoclave and this one is closed 
with a manometer. 
Successively 50 bar of H2 are added to the manometer and evacuated slowly, 
after repeating this procedure three times the reaction is left under slow stirring 
until the completion of the reaction (22h). The H2 left is evacuated slowly and the 
reaction mixture is plugged in a column with DCM. 
Yield: 97% 
 
1H-NMR: 2,93 (dd, 2H, J1= 1,2 Hz, J2= 9 Hz), 3,17 (m, 1H), 3,96 (t, 1H, J= 10,5 
Hz), 4,29 (ddd, 1H, J1= 1,5 Hz, J2= 3,3 Hz, J3= 10,5 Hz), 5,02 (s, 2H), 5,05 (s, 
2H), 6,50 (d, 1H, J= 2,7 Hz), 6,54 (dd, 1H, J1= 2,7 Hz, J2= 8,1 Hz), 6,96 (m, 3H), 
7,14 (m, 2H), 7,26-7,48 (m, 10H) 
13C-NMR: 32,03; 38,04; 70,23; 71,25; 102,63; 108,25; 114,64; 115,28; 127,61; 
127,69; 128,04; 128,12; 128,49; 128,71; 128,75; 130,33; 133,86; 137,16; 137,27; 
155,14; 158,01; 158,49. 
MS-EI: 422(73%), 210 (42%), 106(49%), 105(46%), 91(100%), 77(44%) 
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STEP 6 (Table 6) 
Synthesis of (R)-Equol  (8) 
 
 
Compound 7 (0,2 g, 4,73*10-4 mol) and 10% Pd/BaSO4  (20 mg, 20% m/m) are 
inserted in a flask, dissolved in acetone (5 mL) and the flash is evacuated and 
refilled with H2 3 times. 
The reaction is left under magnetic stirring at r.t. and is monitored by TLC in 
DCM:EtOAc 7:5. 
When the reaction is complete the reaction mixture is plugged in a filter with 
celite and the product is separated in a column with DCM:EtOAc 7:5. 
Yield: 95,1% 
 
1H-NMR: 2,71-2,90 (m, 2H), 2,94-3,08 (m, 1H), 3,89 (t, 1H J= 10,2 Hz), 4,14 
(ddd, 1H J1= 1,8 Hz, J2= 3,6 Hz , J3= 10,5 Hz), 6,18 (d, 1H, J= 2,4 Hz), 6,27 (d, 
1H, J= 8,1 Hz), 6,71 (m, 2H), 6,85 (d, 1H, J= 8,1 Hz), 7,10 (m, 2H), 9,13 (s, 1H), 
9,25 (s, 1H) 
13C-NMR: 31,30; 31,16; 48,59; 70,25; 102,47; 112,55; 115,23; 128,29; 130,04; 
131,64. 
MS-EI: 242(73%), 135(17%), 123(43%), 120(53%), 107(14%), 58(14%) 
[α]D
25: +18,5° (Lit.57 : +23°) 
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Synthesis of D4-Equol
 
 
Compound 4 (1 g, 3,93*10-3 mol) and 10% Pd/C  (50 mg, 20% m/m) are inserted 
in a flask, dissolved in MeOD (25 mL) and the flash is evacuated and refilled with 
D2 3 times. 
The reaction is left under magnetic stirring at r.t. and is monitored by TLC in 
DCM:EtOAc 7:2. 
When the reaction is complete the reaction mixture is plugged in a filter with 
celite and the product is separated in a column with DCM:EtOAc 7:2. 
Yield: 90,7% ; I.P.= >99% 
 
1H-NMR: 3,87 (s, 1H), 4,11 (s, small signal), 6,18 (d, 1H, J= 2,4 Hz), 6,27 (d, 1H, 
J= 8,1 Hz), 6,71 (m, 2H), 6,85 (d, 1H, J= 8,1 Hz), 7,10 (m, 2H), 9,13 (s, 1H), 9,25 
(s, 1H) 
13C-NMR: 31,30; 31,16; 48,59; 70,25; 102,47; 112,55; 115,23; 128,29; 130,04; 
131,64. 
MS-EI: 246(12%), 125(13%), 122(17%), 58(42%) 
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Synthesis of (±) Equol 
 
Compound 4 (1 g, 3,93*10-3 mol) and 10% Pd/C  (50 mg, 20% m/m) are inserted 
in a flask, dissolved in MeOH (25 mL) and the flash is evacuated and refilled with 
H2 3 times. 
The reaction is left under magnetic stirring at r.t. and is monitored by TLC in 
DCM:EtOAc 7:2. 
When the reaction is complete the reaction mixture is plugged in a filter with 
celite and the product is separated in a column with DCM:EtOAc 7:2. 
Yield: 87,1% 
 
1H-NMR: 2,71-2,90 (m, 2H), 2,94-3,08 (m, 1H), 3,89 (t, 1H J= 10,2 Hz), 4,14 
(ddd, 1H J1= 1,8 Hz, J2= 3,6 Hz , J3= 10,5 Hz), 6,18 (d, 1H, J= 2,4 Hz), 6,27 (d, 
1H, J= 8,1 Hz), 6,71 (m, 2H), 6,85 (d, 1H, J= 8,1 Hz), 7,10 (m, 2H), 9,13 (s, 1H), 
9,25 (s, 1H) 
13C-NMR: 31,30; 31,16; 48,59; 70,25; 102,47; 112,55; 115,23; 128,29; 130,04; 
131,64. 
MS-EI: 242(73%), 135(17%), 123(43%), 120(53%), 107(14%), 58(14%) 
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